By Chris Wack
Renovaro Biosciences said Wednesday that it is buying BioSymetrics, an artificial intelligence-driven drug discovery and biomarker identification company.
Renovaro said the transaction will improve its data repository, biomarker discovery capabilities and accelerate translational research.
BioSymetrics' proprietary platform is called Elion, an AI and machine learning engine that uncovers complex biological relationships to speed up the discovery of diagnostics and therapeutics. Its Phenograph platform provides a translational engine that maps human clinical signals to prioritized therapeutic targets.
Renovaro said that through this merger, it will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions.
The transaction is expected to close in March, subject to customary closing conditions and regulatory approvals.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 26, 2025 13:44 ET (18:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.